HomeHome SearchSearch MenuMenu Our productsOur products Who we areWho we are

Early-stage lung cancer patients can also benefit from immunotherapy

by , 06 June 2017
Early-stage lung cancer patients can also benefit from immunotherapy
Researchers discovered long ago that lung cancer patients fighting later stages of the disease can benefit from immunotherapy, a type of cancer treatment that uses substances made by your body or a laboratory to boosts your body's natural defences to fight cancer.

Now, new findings by The Tisch Cancer Institute at Mount Sinai reveal that newly diagnosed lung cancer patients can equally benefit from immunotherapy. Here's the full scoop...

New study finds that early-stage lung cancer patients can equally benefit from immunotherapy

The findings, published in the journal Cell, found that immunotherapy has the potential to address lung cancer while offering a potential treatment.
To reach these findings, study author Miriam Merad, a professor of oncological sciences and of medicine at The Tisch Cancer Institute at Mount Sinai, joined a multidisciplinary team of thoracic surgeons, pathologists and scientists in conducting a comprehensive study initiated when lung cancer patients underwent surgery to have cancerous lesions removed.



Imagine your body starts to sort out its health problems on its own!

There are dozens of testimonies of this using Mother Nature's CBD oil...

CBD oil contains all 21 of the amino acids your body needs to stay in tip-top shape and is the only perfectly balanced combination of omega-3 to omega-6 essential fatty acids (EFAs) on the planet!
Amino acids and EFAs are the building blocks to life. They keep you alive by rebuilding and producing new cells in your body.

The results are astonishing when CBD oil is used to treat:

Click here for more details...
Merad and her team analysed samples of lung tumours, surrounding healthy lung tissue and blood on a cellular level to map out the immune system components present in each patient.
After analysing all the samples, Merad and her team found that stage one lung cancer lesions already harbour immune system components that probably compromise anti-tumour T-cells’ ability to fight cancer, leading to tumour-driven immune changes while providing a breakthrough tool for the future development of immunotherapies such as checkpoint inhibitors.

Researchers suggest one reason how immunotherapy works in early-stage lung cancer patients

The researchers behind the study think immunotherapy is as effective in early-stage lung cancer patients as it is in those fighting later stages of the disease because some of the same immune cells that allow immunotherapy to reverse some late-stage lung cancer are also present just as the disease develops.
“Immunotherapy has mostly been used in advanced or metastatic lung cancer, but its benefit in early-stage tumors remains unknown,” said Merad.
“The standard treatment for early lung cancer is normally surgical removal of the lesions – sometimes with chemotherapy and radiation. Our study reveals that early lung lesions are heavily infiltrated with many different immune cells, suggesting that immunotherapy could also work on very early lesions and potentially lead to a cure by heading cancer off at the pass before it really takes root in the lungs,” she added.
For more information on immunotherapy to treat lung cancer, consult your doctor.

Vote article

Early-stage lung cancer patients can also benefit from immunotherapy
Note: 5 of 1 vote

Related articles

Related articles


Health Solutions